Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811664 · ClinicalTrials.gov registry record · Phase 3
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,923
- Enrollment target
NCT04811664 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,923 participants.
The verdict
NCT04811664, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,923 participants
- Enrollment target
Study Summary
The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
Interventions
- BIOLOGICAL Moderna COVID-19 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,923 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04811664
The ClinicalTrials.gov registry entry for NCT04811664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,923 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moderna COVID-19 Vaccine is the first listed.
NCT04811664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04811664 about?
NCT04811664 is a clinical study titled "A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine". The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
What is the current status of trial NCT04811664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,923 participants. The study started on 2021-03-24. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04811664?
The interventions under investigation include: Moderna COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04811664?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.